Oculis Holding AG and Accure Therapeutics SL have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure’s worldwide development and commercial rights to privosegtor (ACT-01), and in a separate closing, ACT-02, an early-stage preclinical neurology drug candidate.